Journal: EJVES Vascular Forum

Article Title: Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access

doi: 10.1016/j.ejvsvf.2022.01.003

Figure Lengend Snippet: Patient disposition (CONSORT diagram). HAV = human acellular vessel; I/E = inclusion/exclusion.

Article Snippet: Graft and fistula failure can force patients to rely on central venous catheters, which are associated with higher rates of infection, all cause mortality, and cardiovascular events., Biological alternatives may offer improved benefits over other grafts; however, to date, no biological conduits (e.g., xenografts such as Artegraft™ [LeMaitre Vascular, Burlington, MA, USA] and ProCol™ [LeMaitre]) have gained wide clinical adoption., , , The human acellular vessel (HAV), a novel bioengineered alternative for dialysis access, has been reported previously., , , , , The clinical use of the HAV was reported in 60 ESRD subjects over one year (40 in Poland, 20 in the USA) from two phase II trials ( NCT01744418 and NCT01840956 ).

Techniques:

Journal: EJVES Vascular Forum

Article Title: Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access

doi: 10.1016/j.ejvsvf.2022.01.003

Figure Lengend Snippet: Six years of haemodialysis using a human acellular vessel. (A1) Skin over the human acellular vessel (HAV), which has been used for haemodialysis for approximately six years (subject 02-010); black arrow indicates a cannulation zone subjected to needle punctures over the years. (A2) Ultrasound images of the vessel from the same patient, with the conduit diameter being 8–9 mm, greater than the original implantation inner diameter of 6 mm (note cursors extend outside the vessel lumen). (B1, B2) HAV cross sections at 122 weeks. (C1) Immunofluorescence staining in samples explanted at 200 weeks for endothelial progenitor marker CD34 (green) and the endothelial maker CD31 (red) demonstrate CD31 + endothelial cells with neovascularisation present in both the adventitial and medial layer of the HAV. (C2) Immunofluorescence staining for alpha smooth muscle actin (αSMA; red) and calponin 1 (CNN1; green), markers associated with vascular smooth muscle cells, in samples explanted at 200 weeks. In (C1) and (C2) images, nuclei (blue) were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).

Article Snippet: Graft and fistula failure can force patients to rely on central venous catheters, which are associated with higher rates of infection, all cause mortality, and cardiovascular events., Biological alternatives may offer improved benefits over other grafts; however, to date, no biological conduits (e.g., xenografts such as Artegraft™ [LeMaitre Vascular, Burlington, MA, USA] and ProCol™ [LeMaitre]) have gained wide clinical adoption., , , The human acellular vessel (HAV), a novel bioengineered alternative for dialysis access, has been reported previously., , , , , The clinical use of the HAV was reported in 60 ESRD subjects over one year (40 in Poland, 20 in the USA) from two phase II trials ( NCT01744418 and NCT01840956 ).

Techniques: Immunofluorescence, Staining, Marker